The aim of the project is to develop and test a new method to quantify the proportion (percent) of cancer that is residual after neoadjuvant chemotherapy using standard radiologic and/or clinical measures of tumor size that are integrated with pathologic information about the amount of cancer within each tumor. We have determined that tumor cellularity significantly decreases as a result of neoadjuvant (pre-operative) chemotherapy compared to control untreated breast cancers managed by surgery alone. However, the extent and variability of reduction of cellularity is considerable, particularly in the tumors that partly respond, and this shifts the distribution of residual tumor burden closer to complete response in those cases. Overall, this distribution indicates that many breast cancers aýe more responsive to neoadjuvant chemotherapy than measurement of tumor diameter alone would indicate. Therefore, size alone is not a sufficient measure of the tumor response to treatment. We have combined our measure of cancer cellularity with the radiological tumor measurements with the gross and microscopic pathologic changes in the breast and axillary lymph nodes after chemotherapy to determine a measure of relative breast cancer response. This Residual Cancer Index closely correlates with T-stage and appears to organize the responses into a meaningful distribution that allows a detailed view of nonresponsive tumors and can then be used to conduct rank order statistical analyses without dividing the distribution of responses into arbitrary categories. Using this approach we have determined that low proliferation (Ki-67 < 15%), bcl-2 overexpression, and tau overexpression significantly predict greater resistance to neoadjuvant chemotherapy with paclitaxel, 5-FU, doxorubicin, and cyclophosphamide.
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breast cancer, chemotherapy, neoadjuvant, response, pathologic 16. PRICE CODE INTRODUCTION: A more accurate way to measure breast cancer response to treatment would improve the rate of yield of information from clinical trials of neoadjuvant chemotherapy. It would also provide a more useful standard with which to compare the relevance of pathologic findings in residual cancer and with which to test those molecular biomarkers that show promise to predict response to treatment. We are developing and testing a method to quantify tumor response, using clinical, radiologic, and pathologic information that is applicable to most clinical practices. We are comparing the molecular evidence of cell survival and proliferative activity in the residual cancer cells and pathologic changes in the residual carcinoma from neoadjuvant chemotherapy as they relate to the amount of tumor response. The Department of Defense approved the IRB for human subjects research on December 22, 2002. In year one we have identified a cohort of 108 patients who received neoadjuvant chemotherapy for breast cancer and reviewed their pathology materials (see task 2). Pathological data included: tumor size, % invasive cancer, % in situ cancer, % cancer cellularity within the tumor, and cytomorphologic changes within residual cancer cells.
In year two we completed our analysis of the pathological changes in % cancer cellularity before and after neoadjuvant chemotherapy, compared this to the clinical response and pathologic Tstage after treatment. We presented the findings as a poster at the San Antonio Breast cancer Symposium in December, and published these results as a paper in CANCER in March, 2004 . In year two we completed the radiological review of all radiological materials from 85 of these patients (the review of remaining patients' material is ongoing) and combined these results with the pathological data to determine an index score for the proportion of residual cancer burden after chemotherapy relative to the cancer burden before treatment began. In year one the cancer cellularity within the tumor area was measured from hematoxylin and eosin stained tumor sections for the pre-treatment diagnostic core biopsy and the post-treatment Symmans, W.F. resection specimen from 108 breast cancers from women who were treated with pre-operative (neoadjuvant) chemotherapy in the clinical trial (ID98-240). These were compared to the cancer cellularity in the diagnostic core biopsy and the surgical resection specimen from a control group of 120 breast cancers that did not receive pre-operative chemotherapy. The findings were that the % cancer cellularity in an untreated resected breast cancer is slightly higher than in the corresponding diagnostic core biopsy sample obrtained before surgery (40%, versus 30%). However, after neoadjuvant chemotherapy the %cellularity in the residual breast cancer is significantly less than in the pre-treatment core biopsy sample from that patient's tumor (10%, versus 40%). Therefore, neoadjuvant chemotherapy significantly reduces the % cellularity within the breast cancer.
The tumor cellularity in treatment and control groups is summarized using a boxplot. The black rectangle in each case indicates the 25th and 75 percentiles of the distribution with I median indicated by white horizontal lines within j the rectangles. The figure indicates that there C Ron was a significant overall decrease in cellularity of resection specimens compared to biopsy Co,,,w, rp specimens for the treatment group (Paired Wilcoxon signed rank test p-value <0.01), while a significant increasing trend was noted in the percentage of tumor cellularity in patients from the control group (Paired Wilcoxon signed rank J
•itest p-value < 0.01).
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We calculated the relative change in tumor cellularity as follows: Relative change in tumor cellularity = (percentage of tumor cellularity at resection -percentage of tumor cellularity in biopsy) / percentage of tumor cellularity in biopsy. Medians (range) of the change in tumor cellularity in treatment and control groups were -0.67 (-1, 2.6) and 0 (-0.75, 5), respectively. We determined that this is highly variable in different patients' tumors and that it is most obvious in patients who achieve more marked clinical response and those with the least residual breast cancer after treatment. Reduction in cancer cellularity was not seen in those few patients with stable or progressive disease, and was highly variable in patients who achieved minimal or partial response. and progressive disease).
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Categorization by residual pathologic tumor status shows that changes in cellularity were highly variable for all residual tumor classifications (pTl-pT3), but that pTla and pTlb tumors (combined) showed the greatest reduction in cellularity. A minority of tumors in each residual tumor classification had increased cellularity after treatment.
Relative changes in cellularity categorized by tumor stage show that TI a and TI b residual tumors demonstrate the greatest change in cellularity within residual breast cancer.
However, changes in cellularity were found to be ".C The combined product of tumor diameter from the resection specimen and the cancer cellularity within the resected tumor was compared with tumor diameter alone in the treated and control groups. The frequency distribution for tumor size alone is similar in tumors from patients who were treated with surgery alone (A) and from tumors from patients who were treated with neoadjuvant chemotherapy then surgery (B). The product of size and cellularity has a similar distribution in the tumors from patients who were treated with surgery alone (C), but is quite different in the tumors from patients who were treated with neoadjuvant chemotherapy then surgery (D). The shape of that distribution (D) suggests that the population of treated tumors all tend towards a zero product of size and cellularity (complete response) rather than having a skewed normal or bimodal distribution. This appears to be a meaningful pattern of distribution because it suggests that a majority of tumors respond to treatment to some extent. The implication of these graphs is that the incorporation of cancer cellularity (shown to relate to clinical response and pathological T-stage after treatment) as a variable in the overall measurement of tumor response is likely to be an improvement over using size alone. The above analyses were published as an article in CANCER (see references). The combination of residual tumor size and cancer cellularity is an indicator of residual tumor burden, but does not include information about the size and pathological features of the tumor before treatment began.
In year two we have reviewed all the radiological materials from 85 of these patients and have defined a residual cancer index score that includes radiological and histopathological information about the tumor before treatment began as well as gross and histopathological information about the residual primary tumor site in the breast and the axillary nodal basin. A formula was designed to include these variables into a residual cancer index score: The distribution of the residual cancer index (above) is similar to the distribution for the combination of size x cancer cellularity. Values > 2.0 were assigned a score of 2.0. Pathological complete response (pTO NO) was achieved in 18 patients, but a total of 30 patients have a residual cancer index that is close to zero. This indicates a group of patients with residual disease but whose response is nearly complete. The distribution demonstrates a range of responses that could be used as a measure of response for statistical analyses. When the Residual Cancer Index score was compared to the p T-Stage of these tumors the result was highly significant (Kruskal-Wallis test, p<0.0001). One case was omitted due to missing values.
It is encouraging that this Residual Cancer Index score is significantly related to T-Stage of the resudual tumor, because that is a robust indicator of long-term disease-free survival. However, it is also evident from the box plot below that there is variation of the Residual Cancer Index scores within each stage category and overlap across different categories. We suggest that the Residual Cancer Index score might better organize the response of some tumors in the study, such as those with sparse cellularity in a larger area, those with small T-stage but many positive nodes, and small node-positive tumors that were not much affected by treatment. Residual pT-Stage
We have now begun to compare the Residual Cancer Index scores to pathological characteristics in the residual tumors (Task 3) and in the breast cancers before treatment began (Task 4). Task 3 is not yet complete, but an interim analysis of the immunohistochemical staining of residual cancer cells is presented for the available tissues from these patients. Immunohistoichemistry results were dichotomized as follows: Ki-67 > 15% of nuclei defined as positive, bcl-2 cytoplasmic staining intensity > 2+ (range 0 -3) defined as positive, any bcl-6 nuclear staining defined as positive, any NF kappa B nuclear staining defined as positive, p53 > 5% of nuclei defined as positive, any survivin staining defined as positive, tau cytoplasmic staining intensity a 2+ (range 0 -3) defined as positive. There is not consistent or strong relationship between the expression of these biomarkers and residual tumor pT-Stage, residual tumor burden, or residual cancer index. Bcl-2 expression in the residual tumor cells was more common in the higher T-stages and greater proliferation (Ki-67 > 15%) was more common when there was more residual tumor burden (size x cellularity). Task 4 is not yet complete, but an interim analysis of the immunohistochemical staining of residual cancer cells is presented for the available tissues from these patients. Immunohistochemistry results were dichotomized as follows: Ki-67 > 15% of nuclei defined as positive, bcl-2 cytoplasmic staining intensity t 2+ (range 0 -3) defined as positive, p53 > 5% of nuclei defined as positive, tau cytoplasmic staining intensity > 2+ (range 0 -3) defined as positive. Her-2/neu and ER results are being retrieved for all the patients but these have not yet been analyzed. Breast cancers with greater proliferation (Ki-67 > 15%) were associated with smaller residual tumor pT-Stage, less residual tumor burden, and smaller Residual Cancer Index scores. This is a meaningful result because the tumor proliferation index before treatment has been previously shown to be related to greater probability of achieving a complete pathological response, versus residual disease. Breast cancers with bcl-2 overexpression had significantly greater residual tumor pT-Stage, residual tumor burden, and Residual Cancer Index scores. This is an interesting finding Symmans, W.F. because other studies have shown only borderline significance of bcl-2 overexpression to predict complete pathological response versus residual disease. Our analyses demonstrate that bcl-2 overexpression is probably more predictive of the amount of residual tumor burden and higher Residual Cancer Index scores. That makes sense when we consider the underlying hypothesis that bcl-2 overexpression would confer more resistance. It is interesting to note that overexpression of tau protein is associated with a higher Residual Cancer Index score. We identified from a different study using gene expression microarray experiments from pre-treatment FNA tumor samples in a different cohort of patients receiving T/FAC chemotherapy that elevated tau gene expression was strongly predictive of residual disease, versus complete pathological response. We were able to demonstrate in these patients that the immunohistochemical overexpression of tau was related to higher Residual Cancer Index scores (more residual cancer relative to the original tumor burden). In the final year of funding we aim to use immunohistochemistry to investigate the expression of some of the other molecules that we have identified from the gene expression studies.
Task 5. Compilation of patient follow-up from clinical trial database and statistical analyses for disease free interval and survival. (Months 30 -36)
Work on Task 5 is scheduled to begin in year 3 of funding. The cohort of patients who are being studied received sequential chemotherapy with paclitaxel then 5-FU, doxorubicin, and cyclophosphamide (T/FAC) and currently have follow-up of 4 years. A separate population of 80 patients have been identified, all of whom received FAC chemotherapy, and follow-up of at least 8 years is available for all. The pathological and radiological materials are being retrieved for review and those results will used to calculate the Residual Cancer Index score for comparison with time to progression by the end of the funding period. It is hoped that this will determine whether the Residual Cancer Index as a measure of response has prognostic significance.
KEY RESEARCH ACCOMPLISHMENTS:
Key research accomplishments from this study to date are: "* Demonstration that cancer cellularity within the tumor is significantly decreased by neoadjuvant chemotherapy, and is most obvious and variable in the partial response and minimal response (stable disease) categories and, similarly, in tumors staged as T1 after treatment. "* Mathematical definition of a Residual Cancer Index score that incorporates radiological and histopathological information about the tumor before treatment and gross and histopathological information about the residual tumor and axillary nodes after the completion of neoadjuvant chemotherapy. "* Distribution of the residual tumor burden (tumor size x cellularity) and the Residual Cancer Index score demonstrate more clearly than the tumor size alone that many patients respond to neoadjuvant chemotherapy, some closely approximate complete pathological response, and the extent of residual cancer in those with residual disease is variable and can be represented as a distribution. "* These distributions of residual tumor burden and Residual Cancer Index are similar in shape and appear likely to be biologically meaningful and amenable to mathematical modeling. "* These distributions of residual tumor burden and Residual Cancer Index are related to the expression of known predictive biomarkers (Ki-67 and bcl-2) and a new biomarker (tau). The definition, distribution, and correlations of the Residual Cancer Index will be reportable when these studies are completed. Also, the biomarker studies of molecular characteristics in the residual tumors (task 3) and the pre-treatment tumor samples (task 4) will be reportable. Finally, the prognostic follow-up studies (task 5) will also be reportable.
CONCLUSIONS:
1. Assessment of cancer cellularity within the measured tumor bed provides meaningful information about tumor response following therapy. 2. Planned future studies of this variable with radiologic tumor measurements (before and after treatment) from this clinical trial are likely to yield valuable results. 3. Refinement of the assessment of cancer cellularity using cytokeratin immunohistochemical stains will be studied. median of 40% in core needle biopsy to 10% in resection specimens (P < 0.01;
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T he response of primary breast carcinoma to neoHistologic evidence of response to preoperative adjuvant chemotherapy correlates with survival, chemotherapy was investigated previously in bone paPatients who achieve a complete pathologic rethology, in which it was found that the percent tumor sponse are reported to have significantly improved necrosis was the most significant prognostic factor in disease free and overall survival."-Patients with patients with osteosarcoma.1 3 Recently, it was demonsmaller primary tumors are more likely to achieve a strated that categories of histologic change indepencomplete pathologic response. 6 The frequency of dently were predictive of 5-year survival in patients complete pathologic response (3-30%) depends on with breast carcinoma after multimodality therapy."
achieve partial or minor responses, and their progprised of tumor cells, represents a potentially infornosis is variable; therefore, further refinement of mative histologic measure of the differential response response assessment would be informative for this of primary breast tumors to chemotherapy. The ob- 
MATERIALS AND METHODS
•sE Cancer Center (LAB02-010). treated by primary surgical management up to 4 weeks after core needle biopsy. All patients underwent Assessment of Cellularity Within the Tumor core needle biopsy (14-gauge or 18-gauge) of the tuSections of the tumor cross-sectional area were reconmor for initial diagnosis followed by surgical resecstructed from 1) mapping the tissue section code from tion, either as primary management (control group) or the report to the macroscopic description of the tumor after neoadjuvant chemotherapy (treated group). Inbed, 2) known macroscopic tumor dimensions from clusion in this study required the availability of hemathe report, and 3) comparison with available specimen toxylin and eosin-stained histologic sections both radiographs. The boundaries of the tumor area were from the initial core needle biopsy and from the subthen outlined on the slides with ink. Computer-gensequent resection specimen. Pathologic review and erated images of known areas were created in 10% data analysis were conducted in accordance with an increments to simulate different microscopic patterns Institutional Review Board protocol that was apof cancer and were used for initial visual training. I Change in cellularity was defined as (% cellulasrty of resection -% cellularity of core needle biopsy) I % celludarity of core needle biopsy.
Cellularity within the tumor area was assessed from tumor size. Pathologic size was defined as the greatest the slides by estimating the percentage area of the dimension of residual invasive tumor and was categooverall tumor bed that was comprised of invasive turized using the revised American Joint Committee on mor cells. The complete cross-sectional area of the Cancer TNM staging system." tumor bed was studied to account for the heterogeneous distribution of tumor cells within a given tumor Statistical Analyses bed (Fig. 1) . Three pathologists independently reDistributions of cellularity percentages among groups viewed the percentage tumor cellularity in the first 70 are summarized graphically using box plots. The specimens, and there was nearly complete concorshaded rectangles in the box plots delineate the 25th dance between pathologists. One pathologist then and 75th percentiles of each distribution, with the completed the analysis. In specimens with multifocal median indicated by a horizontal white line within the disease, cellularity was assessed in the same tumor rectangle. The outer boundary brackets delineate the mass that had been sampled by core needle biopsy.
2.5th and 97.5th percentiles. Black lines then repreCellularity was recorded in 10% increments from 10% sent individual results outside of this range. The disto 100%, with additional values of 1% and 5% for tributions of 1) residual pathologic tumor size and 2) minimal cellularity. The proportion of invasive carcithe product of residual pathologic tumor size and noma was then calculated.
tumor cellularity are summarized graphically by histograms. Measurements of cellularity in core needle
Clinical Response Categories biopsy and resection specimens were compared using The assessment of clinical response was based on the Wilcoxon signed rank test. All P values presented change in tumor size from pretreatment clinical meaare two-sided, and P values < 0.05 were considered surements to posttreatment clinical and radiologic statistically significant. Statistical analyses were permeasurements. The clinical measurement was the formed using SAS software (version 8.0) and Splus product of the two greatest palpable perpendicular software (version 6.0). The relative change in tumor dimensions of the tumor. Clinical response was catecellularity was computed with the following formula: gorized into four groups: a complete response (CR) relative change in tumor cellularity = (percentage tuwas defined as complete resolution of all tumor demor cellularity at resection -percentage tumor cellutermined by physical examination and imaging studlarity in the core needle biopsy) / percentage tumor ies; a partial response (PR) was defined as incomplete cellularity in the core needle biopsy. Negative values reduction > 50% in tumor size; a minor response (MR) indicated lower cellularity at resection compared with was defined as a reduction in tumor size < 50%; and the core needle biopsy specimen. A minimum value of progressive disease (PD) was defined as an increase in -1.0 was equated with a CR.
Clinical response categories Tumor size distribution, and the median is indicated by the white horizontal line within the rectangle. The outer boundary brackets delineate the 2.5th and 97.5th perclinical CR, 57% PR, 11% stable disease, and 3% PD) centiles, and short horizontal lines represent individual patients outside of this are in agreement with those reported in most studies '-and for this clinical trial. 7 The change in tumor cellularity relative to the starting value in the core RESULTS needle biopsy was compared with clinical response Statistics of the percentage tumor cellularities are preand residual pathologic tumor (pT) status (Table 2) . sented for all groups (Table 1) . Within the treated Relative changes in cellularity were highly variable in group, the median tumor cellularity decreased signifall four clinical response groups, particularly for paicantly from 40% in the core needle biopsies to 10% in tients who achieved a PR or an MR (Table 2 , Fig. 3 ). the resected tumors (P < 0.01; Wilcoxon signed rank Change in cellularity is related to clinical response: test). Tumor cellularity in patients from the control There was a median 50% reduction in tumor cellulargroup increased from a median of 30% (core needle ity in the PR and MR groups (Table 2) , although some biopsy) to 40% (resected tumor; P < 0.01), indicating tumors had increased cellularity, and the few tumors that core needle biopsy specimens may underestimate that progressed had no median change in tumor celthe overall cellularity at resection. These data are sumlularity (Fig. 3) . Categorization by residual pathologic marized in Figure 2 using a box plot.
tumor status shows that changes in cellularity were Clinical response data were available for the 108 highly variable for all residual tumor classifications patients who received T/FAC neoadjuvant chemother-(pTl-pT3), but that pTla and pTlb tumors (comapy. The response rates in the current series (29% bined) showed the greatest reduction in cellularity ( Fig. 4) . Residual pTpa and pTcb tumors had similar response (namely, CR, PR, MR, and PD) are defined by median reductions in cellularity. A minority of tumors the change in tumor size from pretreatment clinical in each residual tumor classification had increased and/or radiologic measurements to posttreatment cellularity after treatment (see Fig. 4 , positive values), clinical, radiologic, and pathologic measurements.
The frequency distributions of pathologic tumor However, residual tumor size is influenced by variable size alone have similar shapes in the control group pathologic changes that occur within the tumor bed.
( Fig. 5A) and the treatment group when pathologic Chemotherapy-induced fibrous stromal involution is CRs are excluded in the treatment group (Fig. 5B ). reported to occur in up to 67% of tumors 16 and can However, the product of pathologic size and tumor result in clinical and macroscopic overestimation of cellularity produces a steeply inversely sloped distriresidual tumor size. There is clearly a role for the bution in the treatment group (Fig. 5D) whereas the development and validation of new histologic ap-"shape of the distribution in control group is similar to proaches to augment the pathologic and clinical asthe distribution for size alone (Fig. 5C) . The product of sessment and to provide information concerning the cellularity and size dramatically changes the distribudifferential response to neoadjuvant chemotherapy, tion of residual tumor pathology in the treated group, particularly for tumors that achieve less than a pathocausing a shift toward CR. This indicates that chemologic CR. therapy in some tumors can reduce cellularity dramatThe current study assessed the role that microically but affects the overall size of the tumor only scopic assessment of tumor cellularity may have in the minimally. We propose that the product of residual pathologist's evaluation of tumor response. There is size and cellularity may be a more clinically relevant precedent for using microscopic assessments of the measure of tumor response than assessing tumor size percentage tumor area or cellularity in breast patholalone.
ogy, such as in the assessment of the amount of intraductal component of tumor sections and in the DISCUSSION assessment of estrogen receptor, progesterone recepClinical trials consistently indicate that the extent of tor, Her-2lneu, and proliferation index (ce-67) immuresponse of primary breast carcinoma to neoadjuvant nostahning. 17 18 In the field of bone pathology, it has chemotherapy correlates with disease-free and overall been shown that histopathologic measurement of the survival.'-The currently used categories of clinical percent tumor necrosis is the most significant prog-jJer FIGURE 6. Two partially responding tumors with a similar decrease in tumor size but with markedly different changes in cellularity after neoadjuvant chemotherapy. (A, B) One tumor decreased from 2.0 cm to 1.8 cm and showed an increase in cellularity. A pretreatment core needle biopsy with a cellularity of 70% is shown in A, and a posttreatment tumor with a cellularity of 80% is shown in B. (C, D) The second tumor decreased from 1.7 cm to 1.5 cm and showed a decrease in cellularity. A pretreatmnent core needle biopsy with a cellularity of 90% is shown in C, and a posttreatment tumor with a cellularity of 5% is shown in D (original magnification × 10).
nostic factor in patients with osteosarcoma who are that achieve a PR of MR and in the different residual treated with preoperative chemotherapy.' 3 We detumor classifications. Figure 6 illustrates two partially fined the size of the residual tumor bed; then, we responsive tumors that had similar decreases in tumor estimated the overall cellularity of invasive tumor size after chemotherapy yet showed markedly differwithin that tumor bed. A potential benefit of this apent changes in cellularity. Changes in tumor size alone proach in the pathologic assessment after chemotherdo not represent response entirely. Tumor cellularity apy is that it bypasses the difficulties in measuring the in patients from the control group increased from a greatest dimension of invasive tumor that is distribmedian of 30% to 40% (P < 0.01), indicating that core uted unevenly within the residual tumor bed as scatneedle biopsy may underestimate the overall cellulartered islands of residual disease. ity at resection. Preferential sampling by core needle The current results showed that the cellularity of biopsy of the fibrotic center in that subset of tumors the tumor mass is reduced significantly by neoadjumay lower the median.' 9 It is possible that artifactual vant chemotherapy and that change is widely variable tissue crushing from the automated core needle bibetween individual patients and in the different cateopsy device may compress the cellular component gories of clinical response and residual tumor sizes. more than the intervening stroma, hence slightly deRelative change in cellularity varies widely in tumors creasing apparent cellularity. There may be differ-
